<DOC>
	<DOCNO>NCT01251796</DOCNO>
	<brief_summary>This phase I study determine safety , tolerability recommend phase II dose ARQ 197 give combination erlotinib primary endpoint CYP2C19 poor metabolizer patient advanced/recurrent non-small-cell lung cancer . The pharmacokinetic profile antitumor activity ARQ 197 administer alone combination erlotinib also determine secondary endpoint .</brief_summary>
	<brief_title>A Study ARQ 197 Combination With Erlotinib</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Voluntary write informed consent study participation must obtain A histologically cytologically confirm advanced/recurrent nonsmallcell lung cancer History ≥1 prior chemotherapy regimen ( treatment EGFR tyrosine kinase inhibitor count one regimen ) ECOG PS 0 1 Life expectancy ≥3 month Poor metabolizers define CYP2C19 genotype Anticancer chemotherapy , anticancer therapy EGFRTKI , hormone therapy , radiotherapy , immunotherapy , investigational agent anticancer antibody therapy within 28 day prior ARQ 197 dose Surgery cancer within 28 day prior ARQ 197 dose Active double cancer Known symptomatic brain metastasis An intercurrent illness uncontrolled ( e.g. , infection , symptomatic congestive heart failure , unstable angina pectoris , symptomatic arrhythmia , interstitial pneumonia ) Pregnant lactate Subjects wish child would agree use contraceptive measure</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>